Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).
Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook mylan stock buy or sell
Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion . Mylan (formerly NASDAQ: MYL) no longer exists as
To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026) Financial Health & Outlook Management expects roughly 2%
The consensus among Wall Street analysts is currently a . While some analysts maintain a "Buy" rating, recent price targets suggest limited immediate upside. Current Stock Price: ~$14.81 (as of April 27, 2026).